Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.
Clinical trial NCT04483219 · UNKNOWN
Trial details
- NCT number
- NCT04483219
- Sponsor
- China Medical University, China
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-24
- Primary completion
- 2022-07-31
- Enrollment
- 53
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.